Healthcare
Scorpius Holdings, Inc.(SCPX)
Live Price
Offline$0.0011
+0.00% today
1Y Change
-72.25%
Window
Jun 23, 2025 โ Jun 11, 2026
- Market Cap
- โ
- Revenue Growth
- -10.7%
- EPS Growth
- +96.2%
- Dividend Yield
- 0.0%
Coverage: 224 bars ยท Jun 23, 2025 โ Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Scorpius Holdings, Inc. (SCPX) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and down 72.2% across the available one-year price window (Jun 23, 2025 โ Jun 11, 2026). Baseline metrics include revenue growth of -10.7%, EPS growth of +96.2%, a dividend yield of 0.0%. What stands out right now is revenue -10.7%, EPS +96.2%, free cash flow +19.8% with operating margin -2538.2% and ROIC -48791205.8%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SCPX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-10.7% vs +7.6% peer median
Operating Margin
Below sector median
-2538.2% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 27, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -10.7% and EPS is at +96.2%, with operating margin around -2538.2%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +1456.2% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 27, 2026 | โ | +0.0% | +16.7% | โ |
2026 Mar 30, 2026 | โ | +15.4% | -23.1% | -91.5% |
2026 Feb 17, 2026 | โ | +1225.0% | +4375.0% | +2900.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SCPX
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
SCPX Max Drawdown
-99.80%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for SCPX and SPY.
Company Overview
Scorpius Holdings, Inc.
Other OTC
Scorpius Holdings Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company provides analytical testing, downstream process development, formulation optimization and development, and clinical biomanufacturing services to pharmaceutical and biotech companies. It is also involved in the provision of pre-clinical and product development; chemistry, manufacturing, and control analytical support; and bioassays. The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024. Scorpius Holdings, Inc. was incorporated in 2008 and is based in Morrisville, North Carolina.
- Leadership
- Jeffrey Alan Wolf
- IPO Date
- Jul 24, 2013
- Employees
- 90
- Street Address
- 627 Davis Drive
- Mailing
- Morrisville, NC, 27560
- Region
- Morrisville, NC, US
- Reporting Currency
- USD
- Investor Line
- 919 240 7133
- Last Updated
- May 4, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 0.0
- Price/Book
- โ
Growth
- Revenue
- -10.7%
- EPS
- +96.2%
- Free Cash Flow
- +19.8%
Profitability
- Gross Margin
- 6.1%
- Operating Margin
- -2538.2%
- Net Margin
- -1793.3%
- ROE
- 427.8%
- ROIC
- -48791205.8%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.10
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.